The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates.
Hopkins
K
K
Imperial Cancer Research Fund, Paediatric and Neuro-Oncology Group, Frenchay Hospital, Bristol, UK.
Papanastassiou
V
V
Kemshead
J T
JT
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005910:Glioma / Q000532:radiotherapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000627:therapeutic use*; D015552:Injections, Intralesional; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D008657:Metabolic Clearance Rate; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage; D012062:Relative Biological Effectiveness; D015996:Survival Rate; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007457:Iodine Radioisotopes; D015021:Yttrium Radioisotopes